Exelixis (EXEL) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Exelixis (EXEL) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 45.47% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 91.31% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Exelixis | 14.44 Bn | 13.66 Bn | 590.86 Mn | 73.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 73.89% |
| Jan 2, 2026 | 116.19% |
| Oct 3, 2025 | 38.28% |
| Jul 4, 2025 | 37.78% |
| Apr 4, 2025 | 32.53% |
| Jan 3, 2025 | 13.69% |
| Sep 27, 2024 | 45.62% |
| Jun 28, 2024 | 33.01% |
| Mar 29, 2024 | 185.65% |
| Dec 29, 2023 | 37.66% |
| Sep 29, 2023 | 26.67% |
| Jun 30, 2023 | 6.70% |
| Mar 31, 2023 | -6.27% |
| Dec 30, 2022 | -57.77% |
| Sep 30, 2022 | -9.09% |
| Jul 1, 2022 | -3.66% |
| Apr 1, 2022 | -3.27% |
| Dec 31, 2021 | -35.83% |
| Oct 1, 2021 | -32.93% |
| Jul 2, 2021 | 3.17% |